Adsett Roger insider trades
Adsett Roger has filed 38 Form 4s with the SEC that we hold, for INSMED Inc (INSM) (Chief Operating Officer), LABP (Director) and Definium Therapeutics, Inc. (DFTX) (Director). Across all of them we count 0 purchases worth $0 and 45 sales worth $62.7M reported on Form 4. In the last 12 months: 0 purchases ($0) and 10 sales ($48.3M). The largest single trade was a sale of 239,850 shares of INSMED Inc worth $32.0M, dated 2026-08-10. The first filing on our record is dated 2022-01-07 and the latest 2026-08-12.
INSMED Inc (INSM)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-01-05 | S, sale reported on Form 4 | 3,068 | $84.7K | 2022-01-07 |
| 2022-01-06 | S, sale reported on Form 4 | 1,759 | $45.7K | 2022-01-07 |
| 2022-01-12 | S, sale reported on Form 4 | 1,217 | $29.9K | 2022-01-13 |
| 2022-05-16 | S, sale reported on Form 4 | 1,394 | $25.7K | 2022-05-18 |
| 2022-05-17 | S, sale reported on Form 4 | 2,022 | $41.1K | 2022-05-18 |
| 2022-11-22 | S, sale reported on Form 4 | 11,855 | $222.9K | 2022-11-22 |
| 2023-01-05 | S, sale reported on Form 4 | 3,044 | $60.1K | 2023-01-06 |
| 2023-01-10 | S, sale reported on Form 4 | 3,194 | $57.5K | 2023-01-12 |
| 2023-05-15 | S, sale reported on Form 4 | 2,847 | $54.9K | 2023-05-17 |
| 2023-05-16 | S, sale reported on Form 4 | 1,521 | $28.0K | 2023-05-17 |
| 2023-05-17 | S, sale reported on Form 4 | 2,448 | $44.4K | 2023-05-17 |
| 2023-06-13 | S, sale reported on Form 4 | 8,981 | $173.5K | 2023-06-15 |
| 2024-01-05 | S, sale reported on Form 4 | 3,042 | $88.9K | 2024-01-05 |
| 2024-01-09 | S, sale reported on Form 4 | 3,837 | $112.2K | 2024-01-11 |
| 2024-01-10 | S, sale reported on Form 4 | 3,536 | $102.2K | 2024-01-11 |
| 2024-01-12 | S, sale reported on Form 4 | 5,251 | $150.3K | 2024-01-12 |
| 2024-05-14 | S, sale reported on Form 4 | 7,857 | $200.4K | 2024-05-15 |
| 2024-05-17 | S, sale reported on Form 4 | 5,945 | $149.2K | 2024-05-17 |
| 2025-01-07 | S, sale reported on Form 4 | 2,444 | $161.2K | 2025-01-10 |
| 2025-01-08 | S, sale reported on Form 4 | 1,882 | $124.4K | 2025-01-10 |
| 2025-01-10 | S, sale reported on Form 4 | 3,604 | $229.3K | 2025-01-10 |
| 2025-01-10 | S, sale reported on Form 4 | 1,298 | $82.9K | 2025-01-10 |
| 2025-01-14 | S, sale reported on Form 4 | 1,457 | $100.1K | 2025-01-16 |
| 2025-02-06 | S, sale reported on Form 4 | 45,605 | $3.7M | 2025-02-07 |
| 2025-02-07 | S, sale reported on Form 4 | 100 | $8.0K | 2025-02-07 |
| 2025-02-10 | S, sale reported on Form 4 | 26,141 | $2.1M | 2025-02-12 |
| 2025-02-10 | S, sale reported on Form 4 | 11,053 | $851.3K | 2025-02-12 |
| 2025-02-10 | S, sale reported on Form 4 | 5,781 | $453.0K | 2025-02-12 |
| 2025-05-13 | S, sale reported on Form 4 | 7,482 | $507.4K | 2025-05-15 |
| 2025-05-14 | S, sale reported on Form 4 | 1,925 | $126.3K | 2025-05-15 |
| 2025-06-03 | S, sale reported on Form 4 | 1,860 | $133.0K | 2025-06-04 |
| 2025-06-16 | S, sale reported on Form 4 | 4,186 | $415.8K | 2025-06-18 |
| 2025-06-16 | S, sale reported on Form 4 | 6,500 | $640.2K | 2025-06-18 |
| 2025-08-19 | S, sale reported on Form 4 | 20,193 | $2.6M | 2025-08-21 |
| 2025-08-19 | S, sale reported on Form 4 | 4,807 | $616.6K | 2025-08-21 |
| 2026-01-06 | S, sale reported on Form 4 | 1,429 | $247.7K | 2026-01-08 |
| 2026-01-07 | S, sale reported on Form 4 | 802 | $140.4K | 2026-01-08 |
| 2026-01-08 | S, sale reported on Form 4 | 2,059 | $358.6K | 2026-01-08 |
| 2026-02-03 | S, sale reported on Form 4 | 791 | $123.5K | 2026-02-04 |
| 2026-04-01 | S, sale reported on Form 4 | 6,715 | $1.1M | 2026-04-03 |
| 2026-04-01 | S, sale reported on Form 4 | 62,344 | $10.3M | 2026-04-03 |
| 2026-04-01 | S, sale reported on Form 4 | 19,001 | $3.1M | 2026-04-03 |
| 2026-05-13 | S, sale reported on Form 4 | 5,837 | $678.1K | 2026-05-15 |
| 2026-06-03 | S, sale reported on Form 4 | 2,370 | $242.4K | 2026-06-05 |
| 2026-08-10 | S, sale reported on Form 4 | 239,850 | $32.0M | 2026-08-12 |
LABP
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Definium Therapeutics, Inc. (DFTX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1685904) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms